Renal Insufficiency, Chronic Clinical Trial
Official title:
How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr)
Background: The prevalence of chronic kidney disease (CKD) is high in Taiwan. Though there
are many factors that may affect the measurement of serum creatinine, it is a well-accepted
marker for renal function assessment. The creatinine clearance (ClCr) estimated by
Cockcroft-Gault is commonly used as a reference for dosage adjustment; while the estimated
glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease (MDRD) is used in
CKD staging. ClCr and eGFR not only have different units, but the results of estimation from
the two varied among races and individuals. Since 2010, US Food and Drug Administration
required both the influences of ClCr and eGFR on the pharmacokinetics of a drug in renal
insufficient patients during pharmacokinetic studies. Because most drugs are excreted
through kidney, an understanding on the relationship between ClCr and eGFR is important to
dose safely and effectively. Furthermore, identifying the factors that may influence the
difference between ClCr and eGFR can provide in-depth consideration during clinical renal
function assessment.
Purpose: The purpose of this study is to analyze the correlation between different ClCr and
eGFR equations in order to provide better renal dose. We also want to find the factors that
may cause the differences between them.
Methods: This study will conduct literature review to understand study population during the
development of different ClCr and eGFR equations, as well as their scope of application.
National Taiwan University Hospital electronic patient database will be used to analyze the
correlation between ClCr and eGFR and to identify factors that may influence the difference
between ClCr and eGFR. The data from patients who have completed 12-hr or 24-hr urine
collection with calculated renal function will be used to verify the applicability of these
equations (including a ClCr equation developed by our institute) in Taiwanese.
Pharmacokinetic principles will be used to analyze the appropriate unit to be used for renal
function while dosing a patient.
Status | Recruiting |
Enrollment | 60000 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - adult patients with serum creatinine test result Exclusion Criteria: - unstable renal function, hemodialysis, cachexia, pregnancy, severe burn, muscle atrophy, severe trauma, amputation, liver failure |
Observational Model: Cohort, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Tapei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference between estimated glomerular filtration rate and creatinine clearance | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
Recruiting |
NCT02947750 -
Neurovascular Transduction During Exercise in Chronic Kidney Disease
|
Phase 2 | |
Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 |